US 10,376,526 B2
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Ulhas R. Dhuppad, Maharashtra (IN); Ashok Katkurwar, Maharashtra (IN); Yashwant Gupta, Maharashtra (IN); Rajesh Ankam, Maharashtra (IN); and Chandrakant Dhatrak, Maharashtra (IN)
Assigned to GLENMARK SPECIALTY S.A., La Chaux-de-Fonds (CH)
Filed by GLENMARK SPECIALTY S.A., La Chaux-de-Fonds (CH)
Filed on Sep. 13, 2017, as Appl. No. 15/703,758.
Application 15/703,758 is a continuation of application No. 15/210,692, filed on Jul. 14, 2016.
Application 15/210,692 is a continuation in part of application No. 15/183,534, filed on Jun. 15, 2016, granted, now 9,750,754.
Application 15/183,534 is a continuation of application No. 14/662,128, filed on Mar. 18, 2015, granted, now 9,370,483.
Application 14/662,128 is a continuation in part of application No. 14/483,837, filed on Sep. 11, 2014, granted, now 9,078,923.
Application 14/483,837 is a continuation in part of application No. PCT/IB2014/064251, filed on Sep. 4, 2014.
Claims priority of application No. 2975/MUM/2013 (IN), filed on Sep. 13, 2013.
Prior Publication US 2018/0000839 A1, Jan. 4, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/58 (2006.01); A61K 9/00 (2006.01); A61K 9/10 (2006.01); A61K 31/335 (2006.01); A61K 47/36 (2006.01); A61K 47/38 (2006.01)
CPC A61K 31/58 (2013.01) [A61K 9/0043 (2013.01); A61K 9/10 (2013.01); A61K 31/335 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01)] 32 Claims
 
1. An aqueous pharmaceutical composition for nasal administration to a human in the form of a suspension comprising mometasone furoate, olopatadine hydrochloride, and a hydrocolloid in an amount sufficient for the suspension to remain in a single phase after 3 months of storage at 25±2° C. and 60%±5% relative humidity.